WSJ's Shira Ovide and Jonathan Rockoff discuss Express Scripts' $29.1 billion deal to acquire fellow pharmacy-benefit manager ...

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

New legislation aimed at lowering drug prices could slam American patients and taxpayers with a multibillion-dollar bill instead. The “Delinking Revenue ...

Express Scripts is a subsidiary of U.S.-based Express Scripts Holding Co., owned by insurance giant Cigna Corp. It is the one of two dominant “pharmacy benefit managers,” or PBMs, in Canada ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Biocon Biologics Ltd., today announced the Company has secured multiple market access agreements for Yesintek™ ...

Health insurers, employers and pharmacy benefit managers may be insulated from the immediate effects of drug tariffs, but ...

Clinical studies showed that Yesintek is a biosimilar to Stelara and has similar pharmacokinetic, safety, efficacy and ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

Health insurance is covering fewer medications, with Medicare patients facing stricter restrictions. Profit-driven ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...